{
    "clinical_study": {
        "@rank": "72143", 
        "acronym": "ROMEO-AD", 
        "arm_group": [
            {
                "arm_group_label": "donepezil maintain group", 
                "arm_group_type": "Other", 
                "description": "continue already taking same dose  (5mg or 10mg per day) of donepezil who assigned donepezil group"
            }, 
            {
                "arm_group_label": "add-on Ebixa oral pump group", 
                "arm_group_type": "Active Comparator", 
                "description": "Ebixa dosage titration (5mg per day  for 1week, then 10mg per day for 1week, then 15mg per day for 1week, then  up to 20mg per day)  add-on already taking donepezil (5mg or 10mg per day)"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the pharmacological efficacy on language capability and compliance\n      with combination of new Ebixa oral pump and donepezil compared to donepezil only in patients\n      with probable  Alzheimer's disease. Primary objective is to evaluate the efficacy of\n      memantine on language capability in moderate to severe   Alzheimer's disease patients who\n      are taking stable donepezil treatment.Secondary objectives are to evaluate the efficacy of\n      maintain on cognitive function and disease progression with K-MMSE, NPI, ROSA, and SIB-short\n      form in probable AD."
        }, 
        "brief_title": "Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Alzheimer's Disease", 
            "Dementia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Alzheimer Disease", 
                "Dementia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  probable Alzheimer's disease in accordance with NINCDS-ADRDA criteria\n\n          -  MMSE score equal to or less than 20\n\n          -  Brain CT or MRI scan performed within the past 12 months\n\n          -  living or having regular visit at least three times a week from caregiver\n\n          -  able to visit outpatient clinic and to perform cognitive function test\n\n          -  already taking stable dose of donepezil for 3 months prior to screening\n\n          -  subject and caregiver who signed informed consent\n\n        Exclusion Criteria:\n\n          -  involved in another clinical trial within 4 weeks prior to screening\n\n          -  severe or unstable disease: acute or severe asthma, unstable or severe cardiovascular\n             disease, acute peptic ulcer,chronic renal failure\n\n          -  bradycardia (pulse rate less than 50bpm), sick sinus syndrome\n\n          -  any laboratory finding including cognitive impairments(vitamine B12 or folic acid,\n             syphilis, thyroid disease)\n\n          -  severe auditory or visual disturbance\n\n          -  other degenerative disease or psychosis\n\n          -  taken any drug used for the treatment of Alzheimer's disease or dementia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "188", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01849042", 
            "org_study_id": "ROMEO-AD 14394A"
        }, 
        "intervention": [
            {
                "arm_group_label": "add-on Ebixa oral pump group", 
                "description": "add-on of Ebixa oral pump already receiving donepezil with stable dosage", 
                "intervention_name": "Ebixa", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "donepezil maintain group", 
                    "add-on Ebixa oral pump group"
                ], 
                "intervention_name": "donepezil", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Memantine", 
                "Donepezil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 7, 2013", 
        "location": {
            "contact": {
                "email": "alzdoc@gw.kuh.ac", 
                "last_name": "Seol-Heui Han, PhD. MD", 
                "phone": "82-10-6309-5630"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "143-729"
                }, 
                "name": "Konkuk university medical center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Randomized, Open-label, Prospective Study to Estimate the add-on Effects of Memantine as Ebixa Oral Pump on Language in Moderate to Severe Alzheimer's Disease Patients Already Receiving Donepezil.", 
        "other_outcome": {
            "measure": "SIB-short form", 
            "safety_issue": "No", 
            "time_frame": "six months"
        }, 
        "overall_contact": {
            "email": "alzdoc@gw.kuh.ac", 
            "last_name": "Seol-Heui Han, PhD. MD", 
            "phone": "82-2-2030-7561"
        }, 
        "overall_contact_backup": {
            "email": "neurohan@kd.ac.kr", 
            "last_name": "Hyun Jeong Han, PhD. MD", 
            "phone": "82-10-4489-8742"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "AQ-WAB(Western aphasia battery)", 
            "safety_issue": "No", 
            "time_frame": "Six months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01849042"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Konkuk University Medical Center", 
            "investigator_full_name": "Seol-Heui Han", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "ROSA (Relevant Outcome Scale for Alzheimer's Disease)", 
            "safety_issue": "No", 
            "time_frame": "six months"
        }, 
        "source": "Konkuk University Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Konkuk University Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}